The company, which trades on the Nasdaq under the ticker TMDX, focuses on portable extracorporeal warm perfusion technology. By assessing donor organ viability before surgery, TransMedics aims to address the critical shortage of usable organs for patients suffering from end-stage heart, lung, and liver failure. Investors and stakeholders can access a live webcast of the session through the company’s investor relations portal, where updated corporate materials are currently hosted. This appearance follows a period of expansion for the firm as it continues to advance its proprietary technology intended to improve clinical outcomes in transplantation.
TransMedics Management to Outline Growth Strategy in Boston
Executives from TransMedics Group will take the stage at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The presentation, scheduled for 2:00 p.m. ET, marks a key opportunity for the Andover-based medical technology firm to detail its progress in organ transplant therapy.
Comments (0)
No comments yet. Be the first!